Verva Pharmaceuticals

Verva Pharmaceuticals Ltd. is a clinical-stage pharmaceutical company advancing novel therapeutics to treat type 2 diabetes, non-alcoholic fatty liver disease (NAFLD/NASH) and related complications. Exciting recent mechanistic results have suggested that Verva technology may have additional application in significant unmet medical needs beyond metabolic disorders.

Verva has successfully completed a randomized, placebo-controlled clinical proof-of-concept study wherein lead molecule VVP808 reduced levels of the diabetes marker HbA1c, improved markers of liver function and caused weight loss in patients with type 2 diabetes.

Verva is now pursuing characterization of the VVP808 novel therapeutic target and the development of proprietary, next generation therapeutics (termed VVP100X) based on the VVP808 structure and novel mode-of-action.